Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $1.6 million.

  • Fulcrum Therapeutics' Depreciation & Amortization (CF) fell 25.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 23.56%. This contributed to the annual value of $1.6 million for FY2024, which is 27.27% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Depreciation & Amortization (CF) stood at $1.6 million, which was down 27.27% from $2.2 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.5 million for FY2021, and its period low was $1.6 million during FY2024.
  • For the 3-year period, Fulcrum Therapeutics' Depreciation & Amortization (CF) averaged around $2.1 million, with its median value being $2.2 million (2023).
  • In the last 5 years, Fulcrum Therapeutics' Depreciation & Amortization (CF) grew by 14.29% in 2020 and then dropped by 27.27% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $2.4 million in 2020, then climbed by 4.79% to $2.5 million in 2021, then decreased by 4.02% to $2.4 million in 2022, then declined by 8.86% to $2.2 million in 2023, then decreased by 27.27% to $1.6 million in 2024.